AI Insight
Researchers investigated whether FDA-approved Toll-like receptor (TLR) agonists BCG and imiquimod could treat oral squamous cell carcinoma by triggering autophagy, a cellular self-degradation process. Both agents induced robust autophagy in cell cultures and animal models, which correlated with reduced tumor size and improved survival rates comparable to cisplatin chemotherapy but with fewer side effects. Imiquimod showed the strongest and most sustained autophagy induction and antitumor activity, establishing a direct mechanistic link between TLR activation, autophagy, and therapeutic efficacy in this cancer type.
Why it matters
This study suggests that repurposing existing FDA-approved immunotherapy drugs could offer safer alternative treatments for oral cancer patients compared to traditional chemotherapy. The findings could accelerate clinical translation since these agents already have established safety profiles and regulatory approval for other indications.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Autophagy and Toll-like receptor (TLR) signaling are both implicated in cancer progression, but whether they act as tumor suppressors or promoters remains unclear. To explore this relationship, we investigated the role of autophagy downstream of therapeutic TLR activation in oral squamous cell carcinoma (OSCC). Using the FDA-approved TLR agonists Bacillus Calmette-Guerin (TLR2/4) and imiquimod (TLR7), we assessed their effects in vitro on SCC-4 cells and in vivo in a chemically induced OSCC hamster model. Both agents, alone or in combination with each other or with Monophosphoryl Lipid-A induced robust autophagy, as measured by LC3B staining in vitro and flow cytometry in vivo. Autophagy induction correlated with reduced tumor volume and prolonged survival, with outcomes comparable to cisplatin, the current standard chemotherapeutic, but with less treatment-associated morbidity and mortality. Autophagy was also associated with cisplatin antitumor effects. Notably, imiquimod produced the most pronounced and sustained autophagic and antitumor effects. To our knowledge, this is the first study to directly link the therapeutic efficacy of TLR agonists in OSCC to autophagy modulation, providing both mechanistic and translational insights into their potential as immunotherapeutic agents.
Source: Autophagy-Mediated Antitumor Effects of BCG and Imiquimod in Oral Squamous Cell Carcinoma